FDA Sets Patent Review Clock for LAZCLUZE Drug
Published Date: 7/14/2025
Notice
Summary
The FDA has officially set the review period for LAZCLUZE, a human drug product, which helps the patent owner apply for extra patent time. This means the company behind LAZCLUZE can extend their patent protection, giving them more time to sell their drug exclusively. If you’re in the drug business or follow patents, this update signals important timing for patent extensions and market control.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Patent extension possible for LAZCLUZE
The FDA has set the regulatory review period for LAZCLUZE, a human drug product. This lets the patent owner submit an application to the U.S. Patent and Trademark Office to extend their patent, which can give the company more time to sell LAZCLUZE exclusively.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-13052, Agency Information Collection Activities; Proposed Collection; Comment Request; Electronic Products
The FDA wants to hear from manufacturers and distributors of electronic products about their reporting and recordkeeping rules. They’re asking for public comments over the next 60 days to make sure the information they collect is clear and useful. This helps keep things running smoothly without extra costs or confusion.
Next: 2025-13054, Determination of Regulatory Review Period for Purposes of Patent Extension; TECELRA
The FDA has officially set the review period for TECELRA, a medicine that helps people, so its patent can be extended. This means the company behind TECELRA can get extra time to protect their invention and keep making money before others can copy it. If you’re involved in drug patents or medicine development, this timing update is a big deal!